CN117717551A - 石蒜碱或其药学上可接受的盐的医药新用途 - Google Patents
石蒜碱或其药学上可接受的盐的医药新用途 Download PDFInfo
- Publication number
- CN117717551A CN117717551A CN202311577534.6A CN202311577534A CN117717551A CN 117717551 A CN117717551 A CN 117717551A CN 202311577534 A CN202311577534 A CN 202311577534A CN 117717551 A CN117717551 A CN 117717551A
- Authority
- CN
- China
- Prior art keywords
- lycorine
- pharmaceutically acceptable
- acceptable salt
- cerebral
- brain injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XGVJWXAYKUHDOO-UHFFFAOYSA-N galanthidine Natural products C1CN2CC3=CC=4OCOC=4C=C3C3C2C1=CC(O)C3O XGVJWXAYKUHDOO-UHFFFAOYSA-N 0.000 title claims abstract description 46
- XGVJWXAYKUHDOO-DANNLKNASA-N lycorine Chemical compound C1CN2CC3=CC=4OCOC=4C=C3[C@H]3[C@H]2C1=C[C@H](O)[C@H]3O XGVJWXAYKUHDOO-DANNLKNASA-N 0.000 title claims abstract description 46
- KQAOMBGKIWRWNA-UHFFFAOYSA-N lycorine Natural products OC1C=C2CCN3C2C(C1O)c4cc5OCOc5cc34 KQAOMBGKIWRWNA-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 150000003839 salts Chemical class 0.000 title claims abstract description 36
- GYKXKOROZFUMIC-UHFFFAOYSA-N 4-[(4-carbamoylphenyl)carbamoylamino]benzenesulfonyl chloride Chemical compound C1=CC(C(=O)N)=CC=C1NC(=O)NC1=CC=C(S(Cl)(=O)=O)C=C1 GYKXKOROZFUMIC-UHFFFAOYSA-N 0.000 claims abstract description 24
- 210000004556 brain Anatomy 0.000 claims abstract description 24
- 208000029028 brain injury Diseases 0.000 claims abstract description 24
- 206010008089 Cerebral artery occlusion Diseases 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 18
- 201000007309 middle cerebral artery infarction Diseases 0.000 claims abstract description 18
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 15
- 210000004925 microvascular endothelial cell Anatomy 0.000 claims abstract description 13
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 11
- 230000007946 glucose deprivation Effects 0.000 claims abstract description 11
- 239000001301 oxygen Substances 0.000 claims abstract description 11
- 230000003542 behavioural effect Effects 0.000 claims abstract description 10
- 230000005779 cell damage Effects 0.000 claims abstract description 8
- 208000037887 cell injury Diseases 0.000 claims abstract description 8
- 230000007774 longterm Effects 0.000 claims abstract description 8
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims abstract description 4
- 206010048962 Brain oedema Diseases 0.000 claims description 6
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- 208000006752 brain edema Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- -1 inhalant Substances 0.000 claims description 3
- 208000029812 Cerebral Small Vessel disease Diseases 0.000 claims description 2
- 206010065384 Cerebral hypoperfusion Diseases 0.000 claims description 2
- 208000022306 Cerebral injury Diseases 0.000 claims description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 abstract description 31
- 208000006011 Stroke Diseases 0.000 abstract description 25
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract description 22
- 230000000302 ischemic effect Effects 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 11
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 10
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 27
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 23
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 23
- 230000006378 damage Effects 0.000 description 17
- 210000002889 endothelial cell Anatomy 0.000 description 15
- VUVNTYCHKZBOMV-NVJKKXITSA-N lycorine hydrochloride Chemical compound Cl.C1CN2CC3=CC=4OCOC=4C=C3[C@H]3[C@H]2C1=C[C@H](O)[C@H]3O VUVNTYCHKZBOMV-NVJKKXITSA-N 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 208000014674 injury Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 230000008499 blood brain barrier function Effects 0.000 description 8
- 210000001218 blood-brain barrier Anatomy 0.000 description 8
- 210000000269 carotid artery external Anatomy 0.000 description 7
- 210000004004 carotid artery internal Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 238000000465 moulding Methods 0.000 description 6
- 230000010410 reperfusion Effects 0.000 description 6
- 210000005013 brain tissue Anatomy 0.000 description 5
- 230000003511 endothelial effect Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002008 hemorrhagic effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000019553 vascular disease Diseases 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- HJXMNVQARNZTEE-UHFFFAOYSA-N Butylphthalide Chemical compound C1=CC=C2C(CCCC)OC(=O)C2=C1 HJXMNVQARNZTEE-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- VJILFEGOWCJNIK-UHFFFAOYSA-N alpha-dihydro-lycorine Natural products C1CN2CC3=CC=4OCOC=4C=C3C3C2C1CC(O)C3O VJILFEGOWCJNIK-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- VJILFEGOWCJNIK-MGRBZGILSA-N dihydrolycorine Chemical compound C1CN2CC3=CC=4OCOC=4C=C3[C@H]3[C@H]2[C@H]1C[C@H](O)[C@H]3O VJILFEGOWCJNIK-MGRBZGILSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241001633628 Lycoris Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003090 exacerbative effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000001578 tight junction Anatomy 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229950005197 butylphthalide Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000009297 electrocoagulation Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013151 thrombectomy Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种石蒜碱或其药学上可接受的盐的医药新用途。本发明首次提供了石蒜碱其药学上可接受的盐在制备预防和/或治疗脑损伤药物中的用途,石蒜碱其药学上可接受的盐在预防和/或治疗脑损伤中效果显著,尤其是在缺血性脑卒中造成的脑损伤,能显著减轻缺血性脑卒中造成的脑损伤。本发明发现了石蒜碱其药学上可接受的盐(例如盐酸石蒜碱、石蒜碱磺酸盐)具有抑制氧糖剥夺引起的脑微血管内皮细胞损伤的作用;具有显著降低大脑中动脉阻塞下脑梗死体积的作用;具有显著改善大脑中动脉阻塞下长期体重和行为学评分的作用,包括石蒜碱或其药学上可接受的盐的药物组合物可以成为新的预防和/或治疗脑损伤药物。
Description
技术领域
本发明属于医药范畴,具体涉及一种石蒜碱或其药学上可接受的盐的医药新用途。
背景技术
脑卒中是当今世界严重危害人类健康和生命安全的难治性疾病,具有高发病率、高致残率、高复发率和高死亡率的特点。根据全球疾病、伤害和危险因素负担研究(GBD)数据:2019年,在全球范围内,脑卒中仍然是第二大死亡原因(占总死亡人数的11.6%)和第三大死亡和致残综合原因(占总数的5.7%)。脑卒中可分为缺血性脑卒中或出血性脑卒中,而缺血性脑卒中占2019年所有新发脑卒中的62.4%。我国是世界上脑卒中疾病负担最严重的国家,每年新发脑卒中患者约200万人。全国每年用于该病的治疗费用达100亿元以上,给国家和家庭造成了沉重的经济负担。在过去的二十年里,大量的研究表明,神经保护剂在动物水平能有效地改善脑缺血症状,但在临床试验中均失败了,这提示仅仅靠神经保护策略来治疗缺血性脑卒中是远远不够的。目前,美国食品和药物管理局批准的唯一缺血性脑卒中治疗方法是重组型组织纤溶酶原激活剂(rtPA)溶栓治疗。但由于治疗时间窗窄(<4.5h),以及涉及脑出血和神经毒性增加的安全性问题,只有极少数脑卒中患者可以接受rtPA治疗。血栓切除术也是一种去除血栓的介入手段,但是小栓子脱落可能会引起严重的术后并发症。因此,研究缺血性脑卒中新的有效治疗手段是当务之急。
脑血管内皮损伤及其引起的血脑屏障破坏是缺血性脑卒中的重要病理机制,从保护内皮细胞入手是缺血性脑卒中治疗的重要手段。脑血管内皮细胞作为神经血管单元和血管神经网络的重要组成部分,是脑微血管系统的主要组成部分和血脑屏障(blood-brainbarrier,BBB)的结构基础,在维持BBB的完整性和正常生理条件下的脑稳态具有主导作用。内皮细胞对缺血和缺氧以及血管系统释放的潜在有害化学物质作出反应,细胞骨架重排、转运增加和紧密连接蛋白的改变发生在缺血后的内皮细胞中,导致血脑屏障功能障碍,氧化应激和炎症可引发不可逆的内皮损伤。首先,缺血条件对脑血管内皮造成直接损伤,破坏内皮细胞结构和功能的完整性;其次,缺血条件激活脑血管内皮细胞,产生内皮炎症,激活的内皮细胞又产生并分泌大量炎性因子,最具代表的炎性因子包括选择素(P-selectin,E-selectin),粘附分子(VCAM-1,ICAM-1)等,这些血管内皮产生的炎性因子促进外周血液循环中的白细胞粘附于内皮细胞进而迁移到脑组织缺血区,进一步通过白细胞产生炎性因子加重脑组织损伤。当脑卒中后受到促炎细胞因子和自由基的刺激时,内皮细胞也是MMPs的来源,有助于内皮紧密连接和细胞外基质的降解。大量研究显示脑缺血引起的脑内皮细胞损伤,内皮细胞炎症,以及随后的内皮功能损伤,共同增加了脑血管通透性和血脑屏障的渗漏,导致缺血性脑损伤。内皮细胞损伤及产生的炎症反应将导致血脑屏障破坏和功能失调,脑血管通透性和完整性改变,血管源性脑水肿,产生炎症因子或促使大量炎症因子进入缺血损伤区,从而加重神经细胞的坏死和凋亡。因此,从保护脑血管内皮细胞入手已成为缺血性脑卒中抑制脑血管功能失调的重要治疗手段。
石蒜碱(Lycorine)是一种从石蒜科石蒜属植物中分离的生物碱类化合物。
发明内容
发明目的:针对现有技术存在的问题,本发明的目的是寻找一种针对减轻氧糖剥夺(OGD)引起的脑微血管内皮细胞损伤的药物,该药物对缺血性脑卒中及其他心、肺、外周血管及其他缺血性血管疾病发挥治疗作用。
技术方案:
一方面,本发明提供石蒜碱或其药学上可接受的盐在制备预防和/或治疗脑损伤药物中的用途。
在一些实施例中,所述脑损伤包括缺血性脑卒中、出血性脑卒中、高原脑水肿造成的脑损伤以及慢性脑缺血与低灌注引起的脑小血管病。
在一些实施例中,石蒜碱或其药学上可接受的盐可明显降低氧糖剥夺(OGD)模型下小鼠脑微血管内皮细胞的损伤;石蒜碱或其药学上可接受的盐可显著降低大脑中动脉阻塞(tMCAO)模型下小鼠的脑梗死体积;石蒜碱或其药学上可接受的盐可明显改善大脑中动脉阻塞(tMCAO)模型下小鼠的长期体重和行为学评分。
因此,石蒜碱或其药学上可接受的盐有望用于治疗包括缺血性脑卒中、出血性脑卒中或高原脑水肿造成的脑损伤在内的多种脑血管疾病。
在一些实施例中,所述石蒜碱药学上可接受的盐可以为盐酸石蒜碱或石蒜碱磺酸盐。
其中,所述盐酸石蒜碱(CAS号:2188-68-3)的化合物结构式如下:
其中,所述石蒜碱或其药学上可接受的盐通过明显降低氧糖剥夺引起的脑微血管内皮细胞损伤,在制备预防和/或治疗脑损伤药物中的用途。
其中,所述石蒜碱或其药学上可接受的盐通过明显降低大脑中动脉阻塞模型下脑梗死体积,在制备预防和/或治疗脑损伤药物中的用途。
其中,所述石蒜碱或其药学上可接受的盐通过明显改善大脑中动脉阻塞模型下长期体重和行为学评分,在制备预防和/或治疗脑损伤药物中的用途。
另一方面,本发明还提供一种用于预防和/或治疗脑损伤的药物组合物,其含有石蒜碱或其药学上可接受的盐或溶剂化物和药学上可接受的载体。
进一步地,在一些实施例中,所述药物组合物的剂型为胶囊剂、散剂、片剂、颗粒剂、丸剂、注射剂、糖浆剂、口服液、吸入剂、霜剂、软膏剂、栓剂或贴剂。
在一些实施例中,所述盐酸石蒜碱的给药浓度为10~50mg/kg,优选为30mg/kg。
上述盐酸石蒜碱的典型但非限制性的给药浓度如为10mg/kg、20mg/kg、25mg/kg、30mg/kg、35mg/kg、40mg/kg或50mg/kg。
进一步地,在一些实施例中,本发明石蒜碱或其药学上可接受的盐的用量为:细胞实验使用0.5、1、2、5、10μM;动物实验中盐酸石蒜碱使用10、30mg/kg。
细胞中的实验结果显示:氧糖剥夺(OGD)明显促进脑微血管内皮细胞中乳酸脱氢酶(LDH)的释放,10μM的石蒜碱及其药学上可接受的盐能够显著抑制乳酸脱氢酶(LDH)的释放。在动物模型上,30mg/kg的盐酸石蒜碱(Lycorine chloride)可显著降低大脑中动脉阻塞(tMCAO)模型小鼠的脑梗死体积,30mg/kg的盐酸石蒜碱(Lycorine chloride)可显著改善大脑中动脉阻塞模型小鼠的长期体重和行为学评分。
有益效果:与现有技术相比,本发明具有如下优点:
本发明首次提供了石蒜碱或其药学上可接受的盐在制备预防和/或治疗脑损伤药物中的用途,石蒜碱或其药学上可接受的盐在预防和/或治疗脑损伤中效果显著,如缺血性脑卒中、出血性脑卒中或高原脑水肿等脑血管疾病造成的脑损伤,尤其是在缺血性脑卒中造成的脑损伤,能有显著减轻缺血性脑卒中造成的脑损伤的作用。
本发明通过实验验证了石蒜碱或其药学上可接受的盐(Lycorine chloride)具有抑制氧糖剥夺(OGD)引起的脑微血管内皮细胞损伤的作用(图1);石蒜碱或其药学上可接受的盐(Lycorine chloride)具有显著降低大脑中动脉阻塞(tMCAO)模型下小鼠的脑梗死体积的作用(图2);石蒜碱或其药学上可接受的盐(Lycorine chloride)具有显著改善大脑中动脉阻塞模型下小鼠长期体重和行为学评分(图3)。本发明的石蒜碱或其药学上可接受的盐(Lycorine chloride)的药物组合物可以成为新型的预防和/或治疗脑损伤药物,治疗包括缺血性脑卒中在内的多种脑血管疾病。
附图说明
图1为本发明实施例中石蒜碱或其药学上可接受的盐(Lycorine chloride)对氧糖剥夺(OGD)引起的脑微血管内皮细胞(bEnd.3)乳酸脱氢酶(LDH)的释放示意图,其中***P<0.001vs Control(CN);#P<0.05,###P<0.001vs OGD,(Graphpad 8.0,one-way ANOVA);
图2为本发明实施例中石蒜碱或其药学上可接受的盐(Lycorine chloride)对短暂性大脑中动脉阻塞(tMCAO)模型小鼠的脑梗死体积的影响示意图;其中***P<0.001vsSham,###P<0.001vs Vehicle,(Graphpad 8.0,one-way ANOVA);
图3为本发明实施例中石蒜碱或其药学上可接受的盐(Lycorine chloride)对短暂性大脑中动脉阻塞(tMCAO)模型小鼠的长期体重和行为学评分的影响示意图;其中*P<0.05vs Vehicle,**P<0.01vs Vehicle,***P<0.001vs Vehicle,(Graphpad 8.0,two-wayANOVA)。
具体实施方式
以下结合附图对本发明做进一步的详细描述,所举实例只用于解释本发明,并非用于限定本发明的范围。
药物及试剂:实施例所用盐酸石蒜碱(Lycorine chloride)从成都曼思特生物科技有限公司购买(CAS号:2188-68-3,商品号A0415),其它试剂为市售的分析纯试剂。
小鼠脑微血管内皮细胞系(bEnd.3)购自中国科学院典型培养物保藏委员会细胞库购买;雄性ICR小鼠购自江苏华创信诺医药科技有限公司,许可证号:SCXK(苏)2020-0009。
实施例1
细胞中乳酸脱氢酶(LDH)释放的测定:
石蒜碱、盐酸石蒜碱、石蒜碱磺酸盐、二氢石蒜碱(10μM)分别预处理脑微血管内皮细胞系(bEnd.3)12h后移除培养基,更换无糖培养基并放置于缺氧培养箱继续培养9h,之后收取细胞上清,使用商品化的乳酸脱氢酶检测试剂盒检测(上海碧云天生物技术有限公司)血管内皮细胞释放的乳酸脱氢酶(LDH)。
(1)体外氧糖剥夺(OGD)内皮细胞损伤模型的建立:
将小鼠脑微血管内皮细胞系bEnd.3以1×105个细胞/ml的密度接种于已预包被I型胶原的24孔板,待稳定24小时后,将孔内培养基更换为含有化合物的新鲜DMEM培养基,作用12小时后,弃去培养基,使用无菌PBS将内皮细胞轻轻洗三遍。加入含有化合物的DMEM无糖培养基,并将其置于三气培养箱中,通入氮气和二氧化碳气体,待培养箱内气体平衡至1% O2、94% N2、5% CO2时开始计时。缺糖缺氧培养9小时后,取出细胞培养板,将各孔中DMEM无糖培养基转移至新的1.5ml离心管中,用于测定LDH释放量。
(2)LDH释放量测定
采用上海碧云天生物技术有限公司生产的LDH检测试剂盒来检测LDH的释放量。OGD损伤会引起大量细胞凋亡或坏死,细胞膜结构被破坏,导致细胞浆内LDH释放到培养基中,通过检测培养基中LDH的活性可以定量测定OGD对细胞的损伤程度。将OGD造模后各孔培养基转移至新的1.5ml离心管,置于4℃保存,当天测定。用INT稀释液将INT(10×)溶液稀释至1×,即为INT工作液。将INT工作液、乳酸溶液、酶溶液等体积混匀,配制成LDH检测工作液。将待测样品加入透明96孔板中,每孔100μl,然后在每孔中分别加入60μl LDH检测工作液,充分混匀后,置于水平摇床上室温避光孵育15分钟。使用多功能酶标仪测定各孔490nm处吸光度;LDH的释放结果见表1和图1。
表1石蒜碱显著降低OGD引起的bEnd.3细胞LDH的释放
以上细胞中的实验结果显示:氧糖剥夺(OGD)明显促进脑微血管内皮细胞中乳酸脱氢酶LDH的释放(如表1和图1所示),10μM的石蒜碱(Lycorine)或其盐酸盐/磺酸盐能够显著抑制乳酸脱氢酶LDH的释放,且相对于二氢石蒜碱(Dihydrolycorine)具有更高的内皮细胞保护活性。
实施例2
小鼠大脑中动脉阻塞(tMCAO)模型的建立及脑梗死体积的测定:
(1)小鼠tMCAO模型建立
小鼠tMCAO模型参考Longa等颈内动脉线栓法。主要操作步骤如下:体重25-30g左右的雄性ICR小鼠称重后,置于麻醉诱导箱中,给予3%-4%异氟烷诱导麻醉,待小鼠麻醉后将小鼠仰卧位固定于手术操作台上。给小鼠戴上呼吸面罩,给予1.0%~2.0%异氟烷维持麻醉状态。用75%酒精棉球擦拭小鼠颈部皮肤,在颈部正中切开皮肤,用弯镊钝性分离各层肌肉和软组织,暴露右侧颈总动脉,置尼龙线备用。沿颈总动脉向小鼠头侧钝性分离软组织,暴露颈外动脉和颈内动脉,注意应避免损伤迷走神经。将颈总动脉和颈内动脉用动脉夹夹闭,在颈外动脉的结扎,用电凝笔将颈外动脉烫断。在颈外动脉的游离残端上剪开一斜切的小口,将硅胶线栓插入颈外动脉,随后将颈外动脉残端与颈内动脉拉成一条直线,将线栓平滑推入颈内动脉,松开颈内动脉动脉夹,继续沿颈内动脉向颅内推动线栓,待感觉到轻微阻力,激光多普勒血流仪检测右侧脑血流下降至造模前25%及以下时认定造模成功。结扎颈外动脉以固定线栓并防止出血,缝合肌肉和皮肤,将小鼠放置于37℃保温箱中维持体温。缺血60分钟后,将小鼠用异氟烷麻醉,缓慢拔出线栓,结扎颈外动脉残端,实现右侧脑血流再灌注,激光多普勒血流仪检测右侧脑血流升高至造模前75%及以上时认定再灌注成功。假手术组小鼠手术操作同造模组,但线栓插入后应立即拔出。
(2)给药方案
称取盐酸石蒜碱7.5mg,溶于1mL的生理盐水中,每只小鼠按照体重计算给药体积,于再灌注时进行尾静脉注射,给药浓度为30mg/kg。假手术组和模型组在再灌注时尾静脉注射同等体积的溶剂。
(3)脑梗死体积测定
采用TTC染色法测定小鼠tMCAO后的脑梗死体积。在缺血后24h,完成神经行为学测试之后,迅速将小鼠脱颈椎安乐死,取出脑组织,立即放入-80℃超低温冰箱。冷冻10分钟后取出,用刀片将脑组织进行冠状面切片,每个大脑平均切成5片。将切好的脑片轻轻置于2%TTC染液中,避光,37℃孵育10分钟。从染液中轻轻取出脑片,排列整齐后拍照保存。经TTC染色的脑片正常组织呈红色,梗死组织呈白色。利用Image J软件计算脑切片的梗死体积以及脑总体积。脑梗死体积百分比即为梗死体积占脑总体积的百分比,其结果如表3和图2所示。
表2盐酸石蒜碱减少小鼠tMCAO损伤后的脑梗死体积
在动物模型上实验结果表明,30mg/kg的盐酸石蒜碱(Lycorine chloride)可显著降低大脑中动脉阻塞(tMCAO)模型小鼠的脑梗死体积,与阳性药丁苯酞(NBP)联用也可以提高治疗效果(表2和图2)。
实施例3
小鼠大脑中动脉阻塞(tMCAO)模型长期实验及行为学评分测定:
(1)小鼠tMCAO模型建立
按实例2方法对小鼠tMCAO造模,假手术组小鼠手术操作同造模组,但线栓插入后应立即拔出。
(2)给药方案
称取盐酸石蒜碱7.5mg,溶于1mL的生理盐水中,每只小鼠按照体重计算给药体积,于再灌注0h、1d、3d、5d、7d进行尾静脉注射,给药浓度为30mg/kg。假手术组和模型组在再灌注0h、1d、3d、5d、7d尾静脉注射同等体积的溶剂。
(3)体重测量和mNSS评分
于造模前以及造模后1d、3d、5d、7d、14d对小鼠体重进行称量记录,观察动物的状态。
小鼠mNSS评分参考以前研究所采用的方法,主要分为行走测试、提尾反应、感觉测定、反射缺失、平衡反应及反常运动5个部分,总分18分。其中得分在1~6分为轻型损伤,7~12分为中型损伤,13~18分为重度损伤,具体评价方法见下表。
mNSS评分细则
表3盐酸石蒜碱改善小鼠tMCAO损伤后的体重下降
表4盐酸石蒜碱改善小鼠tMCAO损伤后的行为学评分
本研究结果统计显示,缺血后3d开始盐酸石蒜碱对小鼠体重下降的情况存在改善作用(表3和图3),Vehicle组小鼠的mNSS评分高达13分,随时间呈现下降的趋势。给予盐酸石蒜碱治疗后,从缺血后3d起,即表现出显著的改善作用,此作用持续到缺血后14d(表4和图3)。
以上实施例,本发明分别从细胞和动物水平上评价了盐酸石蒜碱保护血脑屏障完整性及抗缺血性脑卒中的作用,实验结果表明:盐酸石蒜碱(Lycorine chloride)显著改善了氧糖剥夺(OGD)造成的脑微血管内皮细胞的损伤;在动物模型上,30mg/kg的盐酸石蒜碱(Lycorine chloride)显著地降低了大脑中动脉阻塞(tMCAO)模型小鼠的脑梗死体积和改善行为学评分,这进一步表明石蒜碱及其药学上可接受的盐具有预防和/或治疗脑血管内皮损伤相关的疾病,包括缺血性脑卒中、出血性脑卒中、高原脑水肿、脑小血管病等其它脑血管疾病的潜力,具有重要的应用价值。
Claims (10)
1.石蒜碱或其药学上可接受的盐在制备预防和/或治疗脑损伤药物中的用途。
2.根据权利要求1所述的用途,其特征在于,所述脑损伤包括缺血性脑卒中、出血性脑卒中、高原脑水肿造成的脑损伤以及慢性脑缺血与低灌注引起的脑小血管病。
3.根据权利要求1或2所述的用途,其特征在于,所述石蒜碱或其药学上可接受的盐通过明显降低氧糖剥夺引起的脑微血管内皮细胞损伤,在制备预防和/或治疗脑损伤药物中的用途。
4.根据权利要求1或2所述的用途,其特征在于,所述石蒜碱或其药学上可接受的盐通过明显降低大脑中动脉阻塞模型下脑梗死体积,在制备预防和/或治疗脑损伤药物中的用途。
5.根据权利要求1或2所述的用途,其特征在于,所述石蒜碱或其药学上可接受的盐通过明显改善大脑中动脉阻塞模型下长期体重和行为学评分,在制备预防和/或治疗脑损伤药物中的用途。
6.根据权利要求1或2所述的用途,其特征在于,石蒜碱药学上可接受的盐为盐酸石蒜碱或石蒜碱磺酸盐。
7.根据权利要求6所述的用途,其特征在于,所述盐酸石蒜碱的化学结构式为:
8.根据权利要求6所述的用途,其特征在于,所述盐酸石蒜碱的给药浓度为10~50mg/kg,优选为30mg/kg。
9.一种用于预防和/或治疗脑损伤的药物组合物,其特征在于,其含有权利要求1所述的石蒜碱或其药学上可接受的盐或溶剂化物和药学上可接受的载体。
10.根据权利要求9所述的药物组合物,其特征在于,所述药物组合物的剂型为胶囊剂、散剂、片剂、颗粒剂、丸剂、注射剂、糖浆剂、口服液、吸入剂、霜剂、软膏剂、栓剂或贴剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311577534.6A CN117717551A (zh) | 2023-11-24 | 2023-11-24 | 石蒜碱或其药学上可接受的盐的医药新用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311577534.6A CN117717551A (zh) | 2023-11-24 | 2023-11-24 | 石蒜碱或其药学上可接受的盐的医药新用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117717551A true CN117717551A (zh) | 2024-03-19 |
Family
ID=90204268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311577534.6A Pending CN117717551A (zh) | 2023-11-24 | 2023-11-24 | 石蒜碱或其药学上可接受的盐的医药新用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117717551A (zh) |
-
2023
- 2023-11-24 CN CN202311577534.6A patent/CN117717551A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bywaters | Ischemic muscle necrosis: crushing injury, traumatic edema, the crush syndrome, traumatic anuria, compression syndrome: a type of injury seen in air raid casualties following burial beneath debris | |
Rocha-e-Silva et al. | Small volume hypertonic resuscitation of circulatory shock | |
CN105579045A (zh) | 用于器官停滞、保护和保存以及减少组织损伤的方法 | |
Ellingson et al. | Transplacental passage of ketamine after intravenous administration | |
BR112020019192A2 (pt) | Composição farmacêutica que compreende ácido deoxicólico | |
BR112021001130A2 (pt) | usos de compostos de pirimidina na preparação de medicamentos para prevenir ou tratar esteato-hepatite não alcoólico e fibrose hepática | |
Baillie et al. | Treatment of premature labour with orciprenaline | |
Goldberg | The diagnosis and treatment of sickled erythrocytes in human hyphemas. | |
CN110934857A (zh) | 皮树脂醇在制备预防或治疗脑损伤药物中的用途及其药物组合物 | |
CN117717551A (zh) | 石蒜碱或其药学上可接受的盐的医药新用途 | |
Cavus et al. | Cerebral effects of three resuscitation protocols in uncontrolled haemorrhagic shock: a randomised controlled experimental study | |
RU2675601C1 (ru) | Средство, обладающее противоинсультным действием | |
WO2023087421A1 (zh) | 一种聚合血红蛋白在制备治疗缺血性脑卒中药物的应用 | |
CN102145162B (zh) | 一种治疗早产药物的注射剂 | |
Brodkin | Myoglobinuria following epsilon-aminocaproic acid (EACA) therapy: case report | |
JP7312340B2 (ja) | 水素を含む加齢黄斑変性治療用組成物 | |
WO2021198216A1 (en) | New method to treat the hepatotoxicity induced by amanitins | |
CN111939158A (zh) | 光千金藤碱及其衍生物在制备治疗神经退行性疾病的药物中的应用 | |
WO2009003965A1 (en) | Injectable veterinary composition with anti-prolactin activity | |
Isoa | Current trends in the management of sickle cell disease: an overview | |
Wang et al. | Efficacy of bleomycin-lauromacrogol foam in pediatric macrocystic lymphatic malformations with and without intracapsular hemorrhage | |
CN108309932A (zh) | 一种肌肉注射用青蒿琥酯的溶剂 | |
CN111346230B (zh) | 一种用于术后快速镇痛消肿的医药组合物及其配置方法 | |
US20110003012A1 (en) | Treating patients with subarachnoid hemorrhage | |
CN117122563A (zh) | 一种五倍子酸注射剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |